Alcohol Feeding Impedes Early Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice: Factors in Addition to High-Density Lipoprotein-Apolipoprotein A1 Are Involved

Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model

The French have low coronary heart disease mortality with high fat consumption; this epidemiological anomaly is known as the "French Paradox" and is commonly attributed to the consumption of red wine. However, epidemiology studies have not convincingly shown a superiority of red wine vs. alcohol or other alcoholic beverages. We have used the hamster model of atherosclerosis to determine the active ingredient(s) of red wine responsible for the beneficial effect. Hamsters (nine in each group) were given a cholesterol/saturated fat for 10 weeks to induce foam cell formation. Water or 6.75% ethanol was given to the control groups. Beverages tested included red wine, dealcoholized red wine, and red grape juice, all diluted in half. Ethanol and all beverages caused a significant reduction in atherosclerosis. The combination of ethanol in red wine had the largest effect in decreasing atherosclerosis by both hypolipemic and antioxidant mechanisms. When compared with dealcoholized wine and normalized to polyphenol dose, red wine's beneficial effects can be attributed entirely to the polyphenols. Grape juice had a significant benefit at a much lower dose of polyphenols than the wines. Grape juice was calculated to be much more effective than red wine or dealcoholized red wine at the same polyphenol dose in inhibiting atherosclerosis and improving lipids and antioxidant parameters. This data suggests that polyphenolic beverages from grapes are beneficial in inhibiting atherosclerosis by several mechanisms. Grape juice or non-alcoholic red wine are an excellent alternative to red wine in this model of atherosclerosis.

Atheroprotective mechanisms of HDL

The aim of this review was to bring together results obtained from studies on different aspects of HDL as related to CHD and atherosclerosis. As atherosclerosis is a multistep process, the various components of HDL can intervene at different stages, such as induction of monocyte adhesion molecules, prevention of LDL modification and removal of excess cholesterol by reverse cholesterol transport. Transgenic technology has provided a model for atherosclerosis, and permitted evaluation of the contributions of different HDL components towards the global effect. The availability of apo AIV transgenic mice amplified the results obtained from apo AI overexpressors with respect to prevention of atherosclerosis. Prevention of atherosclerosis in apo E deficient mice by relatively small amounts of macrophage derived apo E may open new possibilities for therapeutic intervention. Contrary to early notions, increased plasma levels of CETP, even in the presence of low but functionally normal HDL, were atheroprotective. The extent to which paraoxonase and apo J participate in prevention of human atherosclerosis needs further evaluation. The findings that LCAT overexpression in rabbits was atheroprotective in contrast to increase in atherosclerosis in h LCAT tg mice, which was only partially corrected by CETP expression, call for some caution in the extrapolation of results from transgenic animals to humans. The important discovery of SR-BI as the receptor for selective uptake of CE from HDL revived interest in the clearance of CE from plasma. This pathway supplies also the vital precursor for steroidogenesis in adrenals and gonads and was shown to be dependent on apo AI.